Female sexual dysfunction in patients with psoriasis and vitiligo: an Egyptian pilot study

Khaled, Hesham N; El-Sabagh, Eman A; Bazid, Heba A. S.

doi:10.4103/jewd.jewd_51_20

Cited by 9 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitiligo varies in severity; the course of the disease is unpredictable and requires lifelong therapy [ 21 ]. Although vitiligo is not life-threatening or physically incapacitating, it can greatly affect a patient’s mental health [ 9 , 10 , 22 ], sexual dysfunction [ 8 , 12 , 15–17 , 23 ], and quality of life [ 11 , 16 , 22 , 23 ]. Since the 1980s, only seven studies [ 8 , 15–17 , 22–24 ] have investigated the possible association between vitiligo and sexual dysfunction.…”

Section: Discussionmentioning

confidence: 99%

“…Although vitiligo is not life-threatening or physically incapacitating, it can greatly affect a patient’s mental health [ 9 , 10 , 22 ], sexual dysfunction [ 8 , 12 , 15–17 , 23 ], and quality of life [ 11 , 16 , 22 , 23 ]. Since the 1980s, only seven studies [ 8 , 15–17 , 22–24 ] have investigated the possible association between vitiligo and sexual dysfunction. Some studies suggest that sexual relationship problems caused by vitiligo are more pronounced in men and single people [ 12 ], while others suggest that they are more pronounced in women [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Four studies [ 8 , 15–17 ] used different evaluation metrics to assess sexual function. Using a random-effects model, combining the results of these trials showed a significant difference in the ASEX scores between the vitiligo and control groups (MD: 4.96; 95% CI: 2.78, 7.13; p < 0.00001; Table 3 , Figure S1 ).…”

Section: Primary Outcomesmentioning

confidence: 99%

“…Two studies [ 15 , 16 ] assessed the participants’ Arabic version of the Female Sexual Function Index (AVFSFI) scores [ 20 ]. Meta-analysis showed that the AVFSFI score of the vitiligo group was significantly lower than that of the control group (MD: −0.73; 95% CI: −1.49, 0.03; p = 0.001; Table 4 , Figure S2 ).…”

Section: Primary Outcomesmentioning

confidence: 99%

See 3 more Smart Citations

Association between vitiligo and sexual dysfunction: current evidence

Liang¹,

Guo

Cai

et al. 2023

Annals of Medicine

View full text Add to dashboard Cite

Background We discovered that vitiligo was associated with sexual dysfunction in clinical diagnosis and treatment; however, no further analysis had been performed due to a lack of data. Objective This study aimed to clarify the relationship between vitiligo and sexual dysfunction. Methods We searched six databases (PubMed, Embase, Cochrane, China National Knowledge Infrastructure, China Science and Technology Journal, and Wanfang Data Knowledge Service Platform) for nearly 40 years. Results According to the search strategy, 91 relevant studies were retrieved, of which 4 were included in the analysis. The Arizona Sexual Experience Scale (ASEX) score (mean difference [MD] 4.96, 95% confidence interval [CI] 2.78–7.13, p < 0.00001) was higher in the vitiligo group than in the control group. The Arabic version of the Female Sexual Function Index (AVFSFI) score (mean difference [MD] − 3.40, 95% confidence interval [CI] − 5.49 to −1.31, p = 0.001) was lower in the vitiligo group than in the control group. Conclusions Patients with vitiligo were found to be at greater risk of sexual dysfunction. Moreover, the association between vitiligo and sexual dysfunction was stronger in women than in men. Key Messages Patients with vitiligo were found to be at greater risk of sexual dysfunction. The association between vitiligo and sexual dysfunction was stronger in women than in men.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Primary Outcomesmentioning

confidence: 99%

Section: Primary Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Association between vitiligo and sexual dysfunction: current evidence

Liang¹,

Guo

Cai

et al. 2023

Annals of Medicine

View full text Add to dashboard Cite

show abstract

“…Measurement of SD varied across studies. Most of the studies relied on 10-item DLQI (n = 3), [11][12][13] and 5 items Arizona Sexual Experience Scale (ASEX) (n = 2), 14,15 followed by other items included 19 items FSFI (n = 2), 16,10 and 12 items General Health Questionnaire (GHQ-12) The prevalence of SD in vitiligo patients ranged from 2.0 to 82.0% in the studies included in this systematic review. The DLQI was utilized in 25.0% of the studies, which is a simple, self-administered, and validated questionnaire designed to measure the health-related QoL of adult patients suffering with a skin disease.…”

Section: Measurement Of Sdmentioning

confidence: 99%

A Systematic Review on Prevalence and Assessment of Sexual Dysfunction in Vitiligo

Saikarthik¹,

Reddy²,

Rafi³

et al. 2022

JAPI

View full text Add to dashboard Cite

Objective: Vitiligo is a common depigmenting disorder with significant psychosocial consequences. Vitiligo has been associated with psychological disorders such as depression, low self-esteem, anxiety, and sexual dysfunction (SD). In recent years, there is an increase in the number of studies looking into the impact of vitiligo on sexual functions. This systematic review investigates the assessment and prevalence of SD in vitiligo patients. Materials and methods: We carried out a systematic search for observational studies on the prevalence of SD in vitiligo patients. The Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) guidelines were used to prepare this systematic review. We searched PubMed, Scopus, Google Scholar, and the Cochrane Library databases. Results: We observed 308 studies for screening. Finally, 12 studies that meet the eligibility criteria were included in this study. The prevalence of SD ranged from 2.7 to 82.0%. Most of the studies used the dermatology life quality index (DLQI) to assess SD. Our findings also show that vitiligo patients were more probably experience symptoms of depression and anxiety, one of the risk factors for SD. Conclusion: Psychological comorbidities are related to a high risk of SD in vitiligo patients. Further prospective longitudinal studies are required to investigate the causal factors for SD in vitiligo patients

show abstract